Atezolizumab - CAS 1380723-44-3

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Apoptosis, Autophagy, PD-1/PD-L1

Cell Cycle/Checkpoint, Autophagy, Immunology/Inflammation, Apoptosis

1380676

0.993

-20°C

Ice Packs

Inhibitory Antibodies